Identification of predictors of response to basal insulin and DPP4 inhibitors in patients with type 2 diabetes failing to other therapies

详细信息    查看全文

• 作者：Matteo Monami ; Benedetta Ragghianti ; Stefania Zannoni…
• 关键词：Diabetes ; Insulin ; DPP4 inhibitors ; Predictors of success
• 刊名：Acta Diabetologica
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：53
• 期：1
• 页码：35-40
• 全文大小：452 KB
• 参考文献：1.Inzucchi SE, Bergenstal RM, Buse JB, Diamant M, Ferrannini E, Nauck M, Peters AL, Tsapas A, Wender R, Matthews DR (2012) Management of hyperglycemia in type 2 diabetes: a patient-centered approach. Position statement of the American diabetes association (ADA) and the European association for the study of diabetes (EASD). Diabetes Care 35:1364–1379PubMedCentral CrossRef PubMed
  2. Rys P, Wojciechowski P, Rogoz-Sitek A, Niesyczyński G, Lis J, Syta A, Malecki MT (2015) Systematic review and meta-analysis of randomized clinical trials comparing efficacy and safety outcomes of insulin glargine with NPH insulin, premixed insulin preparations or with insulin detemir in type 2 diabetes mellitus. Acta Diabetol. doi:10.​1007/​s00592-014-0698-4 PubMedCentral PubMed
  3.Monami M, Marchionni N, Mannucci E (2008) Long-acting insulin analogues versus NPH human insulin in type 2 diabetes: a meta-analysis. Diabetes Res Clin Pract 81:184–189CrossRef PubMed
  4.Kim SC, Glynn RJ, Liu J, Everett BM, Goldfine AB (2014) Dipeptidyl peptidase-4 inhibitors do not increase the risk of cardiovascular events in type 2 diabetes: a cohort study. Acta Diabetol 51:1015–1023PubMedCentral CrossRef PubMed
  5.Monami M, Ahrén B, Dicembrini I, Mannucci E (2013) Dipeptidyl peptidase-4 inhibitors and cardiovascular risk: a meta-analysis of randomized clinical trials. Diabetes Obes Metab 15:112–120CrossRef PubMed
  6.Scirica BM, Bhatt DL, Braunwald E, Steg PG, Davidson J, Hirshberg B, Ohman P, Frederich R, Wiviott SD, Hoffman EB, Cavender MA, Udell JA, Desai NR, Mosenzon O, McGuire DK, Ray KK, Leiter LA, Raz I (2013) SAVOR-TIMI 53 steering committee and investigators. Saxagliptin and cardiovascular outcomes in patients with type 2 diabetes mellitus. N Engl J Med 369:1317–1326CrossRef PubMed
  7.White WB, Cannon CP, Heller SR, Nissen SE, Bergenstal RM, Bakris GL, Perez AT, Fleck PR, Mehta CR, Kupfer S, Wilson C, Cushman WC, Zannad F (2013) EXAMINE investigators. Alogliptin after acute coronary syndrome in patients with type 2 diabetes. N Engl J Med 369:1327–1335CrossRef PubMed
  8.Charlson M, Szatrowski T, Peterson T, Gold J (1994) Validation of a combined comorbidity index. J Clin Epidemiol 47:1245–1251CrossRef PubMed
  9.Brewster LM, Seedat YK (2013) Why do hypertensive patients of African ancestry respond better to calcium blockers and diuretics than to ACE inhibitors and β-adrenergic blockers? A systematic review. BMC Med 11:141PubMedCentral CrossRef PubMed
  10.Kasichayanula S, Liu X, Pe Benito M, Yao M, Pfister M, LaCreta FP, Humphreys WG, Boulton DW (2013) The influence of kidney function on dapagliflozin exposure, metabolism and pharmacodynamics in healthy subjects and in patients with type 2 diabetes mellitus. Br J Clin Pharmacol 76:432–444PubMedCentral CrossRef PubMed
  11.Esposito K, Chiodini P, Capuano A et al (2014) Baseline glycemic parameters predict the hemoglobin A1c response to DPP-4 inhibitors : meta-regression analysis of 78 randomized controlled trials with 20,053 patients. Endocrine 46:43–51CrossRef PubMed
  12.Lim S, An JH, Shin H, Khang AR, Lee Y, Ahn HY, Yoon JW, Kang SM, Choi SH, Cho YM, Park KS, Jang HC (2012) Factors predicting therapeutic efficacy of combination treatment with sitagliptin and metformin in type 2 diabetic patients: the COSMETIC study. Clin Endocrinol (Oxf) 77:215–223CrossRef
  13.Monami M, Cremasco F, Lamanna C, Marchionni N, Mannucci E (2011) Predictors of response to dipeptidyl peptidase-4 inhibitors: evidence from randomized clinical trials. Diabetes Metab Res Rev 27:362–372CrossRef PubMed
  14.UK Prospective Diabetes Study (UKPDS) Group (1998) Effect of intensive blood-glucose control with metformin on complications in overweight patients with type 2 diabetes (UKPDS 34). Lancet 352:854–865CrossRef
  15.Stamou SC, Nussbaum M, Carew JD, Dunn K, Skipper E, Robicsek F, Lobdell KW (2011) Hypoglycemia with intensive insulin therapy after cardiac surgery: predisposing factors and association with mortality. J Thorac Cardiovasc Surg 142:166–173CrossRef PubMed
  
• 作者单位：Matteo Monami (1)
  Benedetta Ragghianti (2)
  Stefania Zannoni (1)
  Valentina Vitale (2)
  Besmir Nreu (1)
  Edoardo Mannucci (2)
  
  1. Division of Geriatric Cardiology and Medicine, Azienda Ospedaliero-Universitaria Careggi, Via delle Oblate 4, 50141, Florence, Italy
  2. Diabetes Agency, Careggi Teaching Hospital, Florence, Italy
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Internal Medicine
  Diabetes
  Metabolic Diseases
  
• 出版者：Springer Milan
• ISSN：1432-5233

文摘

Aim Basal insulin and DPP4 inhibitors are both possible options in patients with type 2 diabetes failing to oral drugs. The identification of clinical predictors of success with either one of the two approaches could be of help in personalizing therapy.